Cargando…
Helicobacter pylori Eradication Therapy, the Reasonable First Line Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Irrespective of Infection Status and Disease Stages
Autor principal: | Cheung, Dae Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003185/ https://www.ncbi.nlm.nih.gov/pubmed/27563015 http://dx.doi.org/10.5009/gnl16359 |
Ejemplares similares
-
Successful Endoscopic Resection of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Unresponsive to Helicobacter pylori Eradication Therapy
por: Choi, Jeongmin
Publicado: (2022) -
Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis
por: Xie, Ya-Lin, et al.
Publicado: (2020) -
Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
por: Gong, Eun Jeong, et al.
Publicado: (2016) -
Role of non-Helicobacter pylori gastric Helicobacters in helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma
por: Lemos, Fabian Fellipe Bueno, et al.
Publicado: (2023) -
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
por: Kuo, Sung-Hsin, et al.
Publicado: (2017)